Research statistics
Davunetide research: publications and trials
At a glance
Publications, all years
174
Since 1999
Publications in 2026 so far
7
Through November 8, 2026
Human clinical research
8.1%
14 of 173 classified
Registered clinical trials
5
ClinicalTrials.gov
Randomized controlled trials
9
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
72.8%
104 animal · 21 in vitro · 1 computational
Records that only mention it
46
Not counted above
Status in the library: In clinical trials. Groups: Cognitive and neurological peptides. 1 publications are not yet classified by study type.
What to keep in mind
- More than 70% of the indexed publications are animal, cell or computational studies.
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Davunetide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1999 | 0 | 1 | 1 | 0 | 2 |
| 2000 | 0 | 3 | 0 | 0 | 3 |
| 2001 | 0 | 2 | 0 | 0 | 2 |
| 2002 | 0 | 5 | 0 | 0 | 5 |
| 2003 | 0 | 3 | 1 | 0 | 4 |
| 2004 | 0 | 5 | 0 | 0 | 5 |
| 2005 | 0 | 8 | 1 | 0 | 9 |
| 2006 | 0 | 9 | 2 | 0 | 11 |
| 2007 | 0 | 10 | 1 | 0 | 11 |
| 2008 | 0 | 6 | 1 | 0 | 7 |
| 2009 | 0 | 9 | 1 | 0 | 10 |
| 2010 | 0 | 8 | 2 | 0 | 10 |
| 2011 | 1 | 6 | 4 | 0 | 11 |
| 2012 | 0 | 5 | 3 | 0 | 8 |
| 2013 | 3 | 5 | 2 | 0 | 10 |
| 2014 | 2 | 8 | 1 | 1 | 12 |
| 2015 | 0 | 2 | 0 | 0 | 2 |
| 2016 | 1 | 4 | 3 | 1 | 9 |
| 2017 | 1 | 6 | 0 | 0 | 7 |
| 2018 | 0 | 1 | 0 | 0 | 1 |
| 2019 | 0 | 5 | 1 | 0 | 6 |
| 2020 | 1 | 0 | 1 | 1 | 3 |
| 2021 | 0 | 2 | 1 | 0 | 3 |
| 2022 | 1 | 1 | 1 | 0 | 3 |
| 2023 | 1 | 2 | 0 | 0 | 3 |
| 2024 | 1 | 6 | 0 | 0 | 7 |
| 2025 | 1 | 0 | 1 | 1 | 3 |
| 2026 (to date) | 1 | 4 | 2 | 0 | 7 |
Study types
| Animal study | 104 |
|---|---|
| Review | 29 |
| In vitro study | 21 |
| Randomized controlled trial | 9 |
| Observational human study | 4 |
| Editorial, letter or other | 3 |
| Case report | 1 |
| Computational study | 1 |
| Meta-analysis | 1 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Neurological and mental health | 148 |
|---|---|
| Cognitive health | 45 |
| Reproductive and sexual health | 16 |
| Cardiovascular | 11 |
| Endocrinology | 9 |
| Metabolic health | 8 |
| Tissue repair | 7 |
| Musculoskeletal | 4 |
| Immune system | 2 |
| Longevity and aging | 2 |
| Antimicrobial and infectious disease | 1 |
| Dermatology | 1 |
Registered clinical trials
1 of 5 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 5
Phase 1: 1 · Phase 2: 3 · Phase 2 / Phase 3: 1
| Trial | Status | Phase | Started | Results |
|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyNCT01110720 · 313 enrolled | Completed | Phase 2, Phase 3 | 2010-10 | — |
| Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyNCT01056965 · 12 enrolled | Completed | Phase 1 | 2010-01 | — |
| A Multicenter Study of NAP (AL-108) in SchizophreniaNCT00505765 · 63 enrolled | Completed | Phase 2 | 2007-07 | Posted |
| Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive ImpairmentNCT00422981 · 144 enrolled | Completed | Phase 2 | 2007-01 | — |
| Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft SurgeryNCT00404014 · 234 enrolled | Completed | Phase 2 | 2006-08 | — |
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.
Psychological medicine · August 23, 2019 · Meta-analysis · cited 216 times · open access
PMID 31439071 · DOI 10.1017/s0033291719001995 · Reviews and meta-analyses
- Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).
Translational psychiatry · October 31, 2025 · Randomized controlled trial · cited 5 times · open access
PMID 41173865 · DOI 10.1038/s41398-025-03675-y · Human clinical research
- Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.
Translational psychiatry · October 2, 2024 · Randomized controlled trial · cited 26 times · open access
PMID 39358355 · DOI 10.1038/s41398-024-03118-0 · Human clinical research
- Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
Translational psychiatry · October 16, 2023 · Randomized controlled trial · cited 26 times · open access
PMID 37845254 · DOI 10.1038/s41398-023-02618-9 · Human clinical research
- CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
Neurology · December 27, 2017 · Randomized controlled trial · cited 112 times · open access
PMID 29282336 · DOI 10.1212/wnl.0000000000004859 · Human clinical research
- Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
Movement disorders : official journal of the Movement Disorder Society · October 1, 2016 · Randomized controlled trial · cited 21 times · open access
PMID 27324431 · DOI 10.1002/mds.26694 · Human clinical research
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
The Lancet. Neurology · May 27, 2014 · Randomized controlled trial · cited 295 times · open access
PMID 24873720 · DOI 10.1016/s1474-4422(14)70088-2 · Human clinical research
- A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
Dementia and geriatric cognitive disorders · April 13, 2013 · Randomized controlled trial · cited 115 times
PMID 23594991 · DOI 10.1159/000348347 · Human clinical research
- Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · January 16, 2013 · Randomized controlled trial · cited 67 times · open access
PMID 23325325 · DOI 10.1038/npp.2013.23 · Human clinical research
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Schizophrenia research · December 12, 2011 · Randomized controlled trial · cited 118 times
PMID 22169248 · DOI 10.1016/j.schres.2011.11.001 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.
Journal of neurochemistry · March 1, 1999 · Animal study · cited 394 times
PMID 10037502 · DOI 10.1046/j.1471-4159.1999.0721283.x · Animal studies
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
The Lancet. Neurology · May 27, 2014 · Randomized controlled trial · cited 295 times · open access
PMID 24873720 · DOI 10.1016/s1474-4422(14)70088-2 · Human clinical research
- Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
The Journal of pharmacology and experimental therapeutics · August 24, 2007 · Animal study · cited 219 times
PMID 17720885 · DOI 10.1124/jpet.107.129551 · Animal studies
- Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Biomaterials · February 27, 2013 · Animal study · cited 217 times
PMID 23453061 · DOI 10.1016/j.biomaterials.2013.02.003 · Animal studies
- An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.
Psychological medicine · August 23, 2019 · Meta-analysis · cited 216 times · open access
PMID 31439071 · DOI 10.1017/s0033291719001995 · Reviews and meta-analyses
Latest publications
- NAP peptide modulated proteome profiling of rat brain cortex under hypobaric hypoxia.
Respiratory physiology & neurobiology · September 11, 2026 · Animal study · cited 0 times
PMID 42727869 · DOI 10.1016/j.resp.2026.104648 · Animal studies
- Dramatic sex differences leading to different brain disease presentation: The requirement for sex-specific medications with ADNP/davunetide as a case study.
Frontiers in neuroendocrinology · August 10, 2026 · Review · cited 0 times · open access
PMID 42575342 · DOI 10.1016/j.yfrne.2026.101274 · Reviews and meta-analyses
- Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.
Annals of medicine · August 7, 2026 · Animal study · cited 0 times · open access
PMID 42568287 · DOI 10.1080/07853890.2026.2705007 · Animal studies
- Activity-dependent neuroprotective protein (ADNP) derived peptide NAP prevents musculoskeletal abnormalities in ovariectomized mice.
Frontiers in neuroscience · July 28, 2026 · Animal study · cited 0 times · open access
PMID 42582414 · DOI 10.3389/fnins.2026.1891428 · Animal studies
- ADNP Functions During Early Brain Development and Their Relevance to ASD and ADNP Syndrome.
International journal of molecular sciences · July 7, 2026 · Review · cited 2 times · open access
PMID 42450350 · DOI 10.3390/ijms27136085 · Reviews and meta-analyses
- Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.
Molecular psychiatry · July 3, 2026 · Observational human study · cited 1 times · open access
PMID 42399413 · DOI 10.1038/s41380-026-03709-x · Human clinical research
- Activity dependent neuroprotective protein mediates the protective effects against VEGF-induced corneal barrier disruption in diabetes.
Peptides · April 7, 2026 · Animal study · cited 0 times
PMID 41956253 · DOI 10.1016/j.peptides.2026.171488 · Animal studies
- Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).
Translational psychiatry · October 31, 2025 · Randomized controlled trial · cited 5 times · open access
PMID 41173865 · DOI 10.1038/s41398-025-03675-y · Human clinical research
- Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity.
Advanced drug delivery reviews · April 2, 2025 · Review · cited 12 times · open access
PMID 40185278 · DOI 10.1016/j.addr.2025.115573 · Reviews and meta-analyses
- Davunetide promotes structural and functional recovery of the injured spinal cord by promoting autophagy.
Neural regeneration research · March 25, 2025 · Not yet classified · cited 22 times · open access
PMID 40145989 · DOI 10.4103/nrr.nrr-d-24-00154 · Not yet classified
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: AL-108; AL-208; Davunetida; Davunetide; NAPVSIPQ
((TITLE_ABS:"AL-108" OR CHEM:"AL-108" OR TITLE_ABS:"AL108" OR CHEM:"AL108") OR (TITLE_ABS:"AL-208" OR CHEM:"AL-208" OR TITLE_ABS:"AL208" OR CHEM:"AL208") OR (TITLE_ABS:"Davunetida" OR CHEM:"Davunetida") OR (TITLE_ABS:"Davunetide" OR CHEM:"Davunetide") OR (TITLE_ABS:"NAPVSIPQ" OR CHEM:"NAPVSIPQ")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 9). Davunetide research statistics (Version weekly-2026-11-08) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/davunetide